Inventor · disambiguated record
Lauric Haber
Also filed as: HABER LAURIC
18 granted patents·11 pending applications·189 citations·filing 2010–2025
94Inventor score
Top patents by PatentIndex Score
29 records- 0197US10772972B2Anti-STEAP2 antibody drug conjugates, and compositions and uses thereofREGENERON PHARMA·Filed 2017·Granted Sep 15, 2020·44 cites·41 claims
- 0297US10179819B2Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereofREGENERON PHARMA·Filed 2016·Granted Jan 15, 2019·25 cites·12 claims
- 0396US10738130B2Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereofREGENERON PHARMA·Filed 2017·Granted Aug 11, 2020·50 cites·49 claims
- 0495US11485793B2Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereofREGENERON PHARMA·Filed 2020·Granted Nov 1, 2022·4 cites·44 claims
- 0595US11155633B2Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereofREGENERON PHARMA·Filed 2018·Granted Oct 26, 2021·9 cites·24 claims
- 0694US12065508B2Multispecific antigen-binding molecules for cell targeting and uses thereofREGENERON PHARMA·Filed 2022·Granted Aug 20, 2024·3 cites·25 claims
- 0794US11952430B2Multispecific antigen-binding molecules for cell targeting and uses thereofREGENERON PHARMA·Filed 2022·Granted Apr 9, 2024·3 cites·24 claims
- 0894US11633501B2Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereofREGENERON PHARMA·Filed 2020·Granted Apr 25, 2023·3 cites·14 claims
- 0994US11548947B2Bispecific anti-PSMA X anti-CD28 antibodies and uses thereofREGENERON PHARMA·Filed 2019·Granted Jan 10, 2023·10 cites·17 claims
- 1093US12077603B2Multispecific antigen-binding molecules for cell targeting and uses thereofREGENERON PHARMA·Filed 2020·Granted Sep 3, 2024·3 cites·28 claims
- 1193US11453721B2Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereofREGENERON PHARMA·Filed 2019·Granted Sep 27, 2022·10 cites·30 claims
- 1293US10941208B2Anti-MUC16 antibodiesREGENERON PHARMA·Filed 2017·Granted Mar 9, 2021·6 cites·2 claims
- 1388US8597652B2Multispecific anti-HER antibodiesFUH GERMAINE·Filed 2010·Granted Dec 3, 2013·10 cites·14 claims
- 1487US9327035B2Anti-HER antibodiesGENENTECH INC·Filed 2013·Granted May 3, 2016·8 cites·13 claims
- 1583US11912767B2EGFR × CD28 multispecific antibodiesREGENERON PHARMA·Filed 2020·Granted Feb 27, 2024·1 cites·16 claims
- 1683US2024368312A1Multispecific antigen-binding molecules for cell targeting and uses thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1781US2025282891A1Anti-PSMA Antibodies, Bispecific Antigen-Binding Molecules that Bind PSMA and CD3, and Uses ThereofREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1876US12344677B2Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereofREGENERON PHARMA·Filed 2021·Granted Jul 1, 2025·0 cites·28 claims
- 1975US12441800B2Bispecific anti-PSMA x anti-CD28 antibodies and uses thereofREGENERON PHARMA·Filed 2022·Granted Oct 14, 2025·0 cites·14 claims
- 2075US12415856B2EGFR x CD28 multispecific antibodiesREGENERON PHARMA·Filed 2023·Granted Sep 16, 2025·0 cites·10 claims
- 2170US2025043002A1BISPECIFIC PD-L1xCD28 ANTIBODIES AND METHODS OF USE THEREOFREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2268US2023279113A1Bispecific Anti-MUC16 x Anti-CD28 Antibodies and Uses ThereofREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2367US2025043017A1BISPECIFIC PD-L1x4-1BB ANTIBODIES AND METHODS OF USE THEREOFREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2464US2025340668A1Multispecific binding molecule proproteins and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2561US2023357446A1Compositions and methods for universal tumor cell killingREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2656US2014193414A1Anti-her antibodiesGENENTECH INC·Filed 2013·Application pending·0 cites
- 2755US2025376524A1Tetravalent multispecific binding molecules and methods of use thereofREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2853US2025297006A1Masked Multispecific Antigen-Binding Molecules with Cleavable LinkersREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2950US2018355038A1Optimized Anti-CD3 Bispecific Antibodies and Uses ThereofREGENERON PHARMA·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Lauric Haber files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →